Omeros (OMER) Reports Encouraging Update from OMS824 Phase 1
Tweet Send to a Friend
Omeros Corporation (Nasdaq: OMER) announced positive results from its Phase 1 clinical program evaluating OMS824, the lead compound from its ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
